Company Overview
Arcutis Biotherapeutics, Inc. operates as a biopharmaceutical company dedicated to the development and commercialization of treatments specifically targeting dermatological diseases. The firm's primary commercial focus rests on ZORYVE, a topical roflumilast cream formulated for the management of plaque psoriasis and atopic dermatitis, alongside an additional development pipeline involving ZORYVE foam. This entity functions within the Healthcare sector and the Biotechnology industry, classifications that define its reliance on rigorous research, regulatory approval processes, and clinical trial execution to bring novel therapies to market. With a market capitalization of $2.84B, annual revenue of $376.07M, and an employee count of 354, the company has established a significant footprint in the dermatology therapeutic landscape. These valuation and revenue figures indicate that Arcutis holds a substantial market position, suggesting that its lead products have achieved meaningful commercial traction relative to its operational scale and workforce size.
Financial Health
The company reported revenue of $376.07M for the trailing twelve months, yet it recorded a net income of $-16,141,000 and an EBITDA of $-7,560,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, likely driven by research and development or commercialization costs, significantly exceed current earnings before interest, taxes, and amortization. Free cash flow stands at $-15,408,750, which indicates that the company is currently consuming cash rather than generating surplus liquidity, a common characteristic for biotechnology firms investing heavily in product expansion. Despite these outflows, the balance sheet maintains a cash reserve of $220.98M against total debt of $114.22M, providing a buffer for ongoing operations. The debt-to-equity ratio is recorded at 60.28, and while the leverage is present, the high cash balance suggests the firm is not in an immediate distress state. Operating liquidity is supported by a current ratio of 3.17, which indicates a robust ability to meet short-term obligations with its available current assets. Return on Equity is -9.3% and Return on Assets is -2.0%, metrics that reveal that management is currently generating negative returns on both shareholder capital and total assets, reflecting the capital-intensive nature of the biotechnology sector where losses are expected prior to widespread product profitability.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the negative net income, while the forward P/E is 17.92. The absence of a trailing P/E combined with a forward P/E of 17.92 implies that the market is pricing in a trajectory of future earnings generation that is expected to turn positive or improve significantly in the coming periods. The price-to-book ratio is 14.92, which indicates that the market values the company's equity at a substantial premium of nearly 15 times its book value, reflecting confidence in the intangible value of its drug pipeline rather than tangible assets. Alternative valuation metrics such as a price-to-sales ratio of 7.56 and an EV/EBITDA of -361.75 suggest that traditional earnings-based valuation models are less applicable, and the market relies heavily on revenue multiples and growth potential to determine worth. The stock's 52-week high is $31.77 and the 52-week low is $11.86, placing the current trading range within a wide band of volatility. The beta value is 1.74, meaning the stock exhibits 74% higher volatility than the broader market, indicating that price movements will likely be amplified relative to general market shifts.
Growth & Income
Revenue growth year-over-year is 81.5%, while earnings growth is N/A due to the company's current unprofitable status. The fact that earnings growth is not applicable while revenue is growing rapidly implies that top-line expansion is currently decoupled from bottom-line profitability, a typical phase for commercializing biologic products where volume scales before margins fully materialize. As a non-dividend payer, the company does not offer a dividend yield or has a payout ratio of 0.0%, which means the firm reinvests all available earnings and cash flow back into research, development, and commercial infrastructure to fuel future growth rather than distributing income to shareholders. This profile summarizes a capital-growth strategy where investors are compensated through potential future appreciation in stock value and market share consolidation rather than current income distributions, relying on the successful transition of ZORYVE and its foam formulation from growth drivers to profit generators.